Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13014163 | 1.00 | OPRK1 (0.42) | OPRK1KCNJ1KCNH2KDM4ENPC1 | |
| SCHEMBL408756 | 0.95 | KCNJ1 (0.43) | OPRK1KCNJ1KCNH2KDM4ENPC1 | |
| SCHEMBL18021169 | 0.92 | SIGMAR1 (0.41) | OPRK1KCNJ1KCNH2CCR2SIGMAR1 | |
| SCHEMBL3783192 | 0.90 | SLC6A9 (0.34) | OPRK1KCNJ1KCNH2KDM4ENPC1 | |
| SCHEMBL18021181 | 0.89 | SIGMAR1 (0.41) | OPRK1KCNJ1KCNH2ALDH1A1CCR2 | |
| SCHEMBL3769255 | 0.87 | KCNJ1 (0.46) | OPRK1KCNJ1KCNH2KDM4ENPC1 | |
| SCHEMBL3249763 | 0.87 | KCNJ1 (0.46) | OPRK1KCNJ1KCNH2KDM4ENPC1 | |
| SCHEMBL18021163 | 0.85 | SIGMAR1 (0.50) | OPRK1KCNJ1KCNH2KDM4ENPC1 | |
| SCHEMBL17986201 | 0.85 | KCNJ1 (0.45) | OPRK1KCNJ1KCNH2KDM4ENPC1 | |
| SCHEMBL18021164 | 0.84 | SIGMAR1 (0.44) | OPRK1KCNJ1KCNH2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360237-A1 | TARGETING SYSTEM FOR CANCER TREATMENT | Coretag IP B.V. (NL) | 2025-11-27 | — | — | US | claimed |
| EP-4615507-A1 | TARGETING SYSTEM FOR CANCER TREATMENT | Coretag IP B.V. (NL) | 2025-09-17 | — | — | EP | claimed |
| WO-2024101993-A1 | TARGETING SYSTEM FOR CANCER TREATMENT | Coretag IP B.V. (NL) | 2024-05-16 | — | — | WO | claimed |
| US-20230348378-A1 | SMALL MOLECULE ALBUMIN BINDERS | OREGON HEALTH & SCIENCE UNIVERSITY | 2023-11-02 | — | — | US | claimed |
| WO-2022040607-A1 | SMALL MOLECULE ALBUMIN BINDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-02-24 | — | — | WO | claimed |
| US-20250360237-A1 | TARGETING SYSTEM FOR CANCER TREATMENT | Coretag IP B.V. (NL) | 2025-11-27 | — | — | US | disclosed |
| EP-4615507-A1 | TARGETING SYSTEM FOR CANCER TREATMENT | Coretag IP B.V. (NL) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024101993-A1 | TARGETING SYSTEM FOR CANCER TREATMENT | Coretag IP B.V. (NL) | 2024-05-16 | — | — | WO | disclosed |
| US-20230348378-A1 | SMALL MOLECULE ALBUMIN BINDERS | OREGON HEALTH & SCIENCE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| WO-2022040607-A1 | SMALL MOLECULE ALBUMIN BINDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-2396040-B1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | GUERBET SA (FR) | 2017-04-05 | — | — | EP | disclosed |
| US-8986650-B2 | Complex folate-NOTA-Ga68 | GUERBET (FR) | 2015-03-24 | — | — | US | disclosed |
| US-20120064003-A1 | COMPLEX FOLATE-NOTA-Ga68 | GUERBET (FR) | 2012-03-15 | — | — | US | disclosed |
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | GUERBET (FR) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360237-A1 | TARGETING SYSTEM FOR CANCER TREATMENT | FOLH1, EGFR, CD47 | OPRK1 2067/4885KCNJ1 4833/4885KCNH2 4837/4885 |
| US-20120009124-A1 | USE OF BUFFERS FOR RADIONUCLIDE COMPLEXATION | CA5B, CA3, CA1 | OPRK1 4442/4885KCNJ1 4043/4885KCNH2 1860/4885 |
| US-20120064003-A1 | COMPLEX FOLATE-NOTA-Ga68 | FOLR1, FOLR2, DHFR | OPRK1 3514/4885KCNJ1 4800/4885KCNH2 4549/4885 |
| US-20230348378-A1 | SMALL MOLECULE ALBUMIN BINDERS | ALB, FABP1, FABP3 | OPRK1 4384/4885KCNJ1 4872/4885KCNH2 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.